Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects

Kenvue Inc. KVUE, the world's leading pure-play consumer health company, delivered year-over-year improvement in second-quarter 2026, although earnings and sales slightly missed the respective Zacks Consensus Estimate. Net sales rose 3% year over year to $3.96 billion, while organic sales increased 1.6%. Kenvue's second-quarter 2026 top-line performance improved meaningfully from the year-ago period, marking a sharp reversal from the reported sales decline of 4.0% and organic sales drop of 4.2%.

Profitability strengthened year over year. On the bottom line, Kenvue adjusted earnings of 31 cents per share increased 6.9% year over year in second-quarter 2025. The increase shows that the company benefits from tighter cost control and operating improvements.  The quarter extended the improvement seen at the start of 2026, with organic growth supported by a combination of higher prices and improved volume trends. Kenvue delivered its third consecutive quarter of net and organic sales growth, with broad-based gains across all segments and regions. (Read more: KVUE Q2 Earnings Miss Estimates as Margins Narrows, Sales Rise)

We note that Kenvue’s shares have declined 3.2% since it released its second-quarter results on Aug. 6, 2026, before market open. The decline may be attributable to the company’s soft quarterly performance, as both adjusted earnings and revenues fell short of the Zacks Consensus Estimate. However, shares of the Zacks Rank #3 (Hold) company have jumped 10.1% in the past three months compared with the industry's growth of 6.1%.

Image Source: Zacks Investment Research

KVUE's Q2 Key Financial Metrics Discussion

Kenvue's three operating segments remain central to its trajectory: Self Care, Skin Health and Beauty, and Essential Health. Skin Health and Beauty remained the key growth driver in the reported quarter, supported by broad-based gains across regions, with Hair Care and Face Care leading the performance. Strong e-commerce momentum, disciplined commercial execution and demand for products such as OGX Pro Growth + Peptide and Neutrogena Ultra Sheer Sun further supported results.

Skin Health and Beauty sales increased 5.1% year over year to $1,113 million, exceeding the Zacks Consensus Estimate of $1,091 million. Organic sales increased 3.7% on higher pricing and volumes, while foreign exchange also contributed to the upside.

Self Care sales increased 2.2% to $1,589 million; however, the metric missed the Zacks Consensus Estimate of $1,617 million. Organic sales rose 0.6% year over year on higher pricing and positive foreign currency, somewhat offset by weak volumes.

Essential Health sales increased 2.3% to $1,253 million, missing the Zacks Consensus Estimate of $1,274 million. However, organic sales rose 1.1%, as volume growth more than offset unfavorable pricing mix. Foreign currency aided results.

What’s More For KVUE?

Beyond the quarterly numbers, the pending Kimberly-Clark transaction remains a major strategic factor. Kenvue is simultaneously pursuing restructuring and operational-efficiency initiatives while preparing for the combination, which management expects to close in the fourth quarter of 2026, subject to foreign regulatory approvals and other customary conditions.

Kenvue is focused on strengthening its leading consumer health brands through innovation, targeted marketing and improved execution. The company is prioritizing its largest brands and markets while investing in new products that address evolving consumer needs. KVUE is also expanding its e-commerce and digital capabilities to improve consumer engagement. It is leveraging its global footprint to expand across international markets and drive growth in core categories.

The company continued to enhance operational efficiency while increasing strategic investments to support sustainable growth. Management noted that first-half 2026 results met or surpassed expectations across core metrics, underscoring the resilience of its brands and the progress of strategic execution. Kenvue remains focused on transformation, improving business performance and driving long-term growth.

Stocks to Consider in the Consumer Staples Space

United Natural Foods UNFI, which is the leading distributor of natural, organic and specialty food and non-food products, currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. 

The Zacks Consensus Estimate for United Natural Foods’ current financial-year sales indicates a drop of 2.1% from the prior-year level. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.

Medifast, Inc. MED, which is a leading manufacturer and distributor of clinically-proven healthy living products and programs, currently carries a Zacks Rank #2 (Buy). MED missed the average earnings surprise by a sharp margin in the trailing four quarters. 

The Zacks Consensus Estimate for Medifast’s current financial-year sales indicates a decline of 25.9% from the year-ago number. 

Freshpet, Inc. FRPT, which manufactures and markets natural fresh foods, refrigerated meals, and treats for dogs and cats, currently carries a Zacks Rank of 2. 

The Zacks Consensus Estimate for Freshpet’s current financial-year sales indicates growth of 10.7% from the prior-year level. FRPT delivered a trailing four-quarter earnings surprise of 21.9%, on average.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research